PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17284012-6	2007	For microwave heating, 30 s was sufficient for carrying out the tryptic digestion of cytochrome c, in the presence of magnetite beads, while 1 min was adequate for tryptic digestion of myoglobin.	Ferrosoferric Oxide	118-127	cytochrome c, somatic	Homo sapiens	85-97
16978766-1	2007	In this work the sorption of As(III) and As(V) on different natural iron oxides (hematite, magnetite, and goethite) has been studied as a function of different parameters.	Ferrosoferric Oxide	91-100	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	41-46
16768484-1	2006	The deposition of colloidal magnetite particles onto graphite and mica surfaces induced by solvent evaporation is studied using atomic force microscopy.	Ferrosoferric Oxide	28-37	MHC class I polypeptide-related sequence A	Homo sapiens	66-70
15752777-1	2005	A cascading polyamidoamine (PAMAM) dendrimer was synthesized on the surface of magnetite nanoparticles to allow enhanced immobilization of bovine serum albumin (BSA).	Ferrosoferric Oxide	79-88	albumin	Homo sapiens	146-159
16448661-1	2006	The adsorption of Co2+ ions from nitrate solutions using iron oxide nanoparticles of magnetite (Fe3O4) and maghemite (gamma-Fe2O3) has been studied.	Ferrosoferric Oxide	85-94	complement C2	Homo sapiens	18-21
16771558-1	2006	Spin-dependent electron transport in individual magnetite (Fe3O4) nanowires contacted with normal metallic electrodes was investigated.	Ferrosoferric Oxide	48-57	spindlin 1	Homo sapiens	0-4
11466312-8	2001	Similar Ca(2+) transients were induced by force application to anti-N-cadherin antibody-coated magnetite beads.	Ferrosoferric Oxide	95-104	cadherin 2	Homo sapiens	68-78
15757336-1	2005	The influence of amine buffers on carbon tetrachloride (CCl4) reductive dechlorination by the iron oxide magnetite (FeIIFeIII2O4) was examined in batch reactors.	Ferrosoferric Oxide	105-114	C-C motif chemokine ligand 4	Homo sapiens	56-60
15452625-1	2004	The magnetic oxides NaFeP(2)O(7) and LiFeP(2)O(7), made up of FeO(6) octahedra containing high-spin Fe(3+)(d(5)) ions, undergo a three-dimensional antiferromagnetic ordering at low temperatures.	Ferrosoferric Oxide	4-19	spindlin 1	Homo sapiens	95-99
15279897-0	2004	Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia.	Ferrosoferric Oxide	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
15046341-4	2004	RDX is transformed by Fe(II) in aqueous suspensions of magnetite (Fe3O4).	Ferrosoferric Oxide	55-64	radixin	Homo sapiens	0-3
15046341-5	2004	Negligible transformation of RDX occurred when it was exposed to Fe(II) or magnetite alone.	Ferrosoferric Oxide	75-84	radixin	Homo sapiens	29-32
15046341-11	2004	The degradation of RDX by Fe(II)-magnetite suspensions indicates a possible remedial option that could be employed in natural and engineered environments where iron oxides are abundant and ferrous iron is present.	Ferrosoferric Oxide	33-42	radixin	Homo sapiens	19-22
12324467-3	2002	We found that in fibroblasts, application of tensile forces through collagen-coated magnetite beads to cell surface beta(1) integrins induced filamin-A expression.	Ferrosoferric Oxide	84-93	filamin A	Homo sapiens	142-151
16349369-10	1994	The temporary co-adhesion to magnetite and TiO(2) was exploited for the design of a prototype biomagnetic separation process in which bacterial cells serve as an adhesive mediator between magnetite and TiO(2) particles in a mixture of Al, Si, and Ti oxides that simulates their proportion in the ash.	Ferrosoferric Oxide	29-38	tiptop	Drosophila melanogaster	202-205
11292176-4	2001	Magnetically-generated tensile forces (approximately 500 pN/cell) applied through collagen-coated magnetite beads selectively reduced SMA but not beta-actin mRNA and protein content in both cell types.	Ferrosoferric Oxide	98-107	immunoglobulin mu binding protein 2	Mus musculus	134-137
10698770-6	2000	The poorly crystalline Fe(III) oxide was reduced to extracellular magnetite.	Ferrosoferric Oxide	66-75	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	26-29
11226210-0	2001	Truncated hexa-octahedral magnetite crystals in ALH84001: presumptive biosignatures.	Ferrosoferric Oxide	26-35	hexosaminidase subunit alpha	Homo sapiens	10-14
9922163-1	1998	A complex between native, iron(II) soybean lipoxygenase 3 and 4-nitrocatechol, a known inhibitor of the enzyme, has been detected by isothermal titration calorimetry and characterized by X-ray crystallography.	Ferrosoferric Oxide	26-33	linoleate 9S-lipoxygenase-4	Glycine max	43-55
8782177-1	1996	Magnetite nanoparticles, coated by three different artificial polypeptides, were conjugated to an antibody specific to the carcinoembryonic antigen (CEA).	Ferrosoferric Oxide	0-9	carcinoembryonic antigen gene family	Mus musculus	123-147
8782177-1	1996	Magnetite nanoparticles, coated by three different artificial polypeptides, were conjugated to an antibody specific to the carcinoembryonic antigen (CEA).	Ferrosoferric Oxide	0-9	carcinoembryonic antigen gene family	Mus musculus	149-152
16349369-10	1994	The temporary co-adhesion to magnetite and TiO(2) was exploited for the design of a prototype biomagnetic separation process in which bacterial cells serve as an adhesive mediator between magnetite and TiO(2) particles in a mixture of Al, Si, and Ti oxides that simulates their proportion in the ash.	Ferrosoferric Oxide	188-197	tiptop	Drosophila melanogaster	43-46
34912778-1	2021	Cellulose, as a green and available phytochemical, was immobilized on the surface of magnetite nanoparticles then doped with imidazole and Co. complex (Fe3O4@CNF ~ ImSBL ~ Co.) and used as a water-dispersible, recyclable and efficient nano catalyst for the synthesis of C-C cross-coupling reactions including fluoride-free Hiyama and Suzuki reactions in an aqueous medium as an efficient and vital solvent, due to their high application and importance in various fields of science.	Ferrosoferric Oxide	85-94	NPHS1 adhesion molecule, nephrin	Homo sapiens	158-161
2166318-0	1990	[Magnet resonance spectroscopy of tumor-bearing rat livers: magnetite particles as an aid in volume selection].	Ferrosoferric Oxide	60-69	activation-induced cytidine deaminase	Rattus norvegicus	86-89
34252429-10	2021	This study reveals efficient toxic Cr6+ removal from effluent using magnetite carbon nanocomposites which extends their application in waste water treatment.	Ferrosoferric Oxide	68-77	teratocarcinoma-derived growth factor 1 pseudogene 6	Homo sapiens	35-38
34091282-2	2021	In this work, we designed a facile and highly specific surface plasmon resonance (SPR) biosensor to detect PD-L1 in human plasma based on magnetite nanorods containing ordered mesocages (MNOM) and silver nanoclusters (AgNCs).	Ferrosoferric Oxide	138-147	CD274 molecule	Homo sapiens	107-112
34445190-5	2021	Distinguishability of MF from NF may be useful in non-invasive MRI diagnosis of pathological processes associated with iron accumulation and magnetite mineralization (e.g., neurodegenerative disorders, cancer, and diseases of the heart, lung and liver).	Ferrosoferric Oxide	141-150	neurofascin	Homo sapiens	30-32
34551040-2	2021	Here, through density functional calculations, we investigated the effect of the spin-orbit interaction on the magnetic ground state of Eu doped magnetite (Fe3O4:EuFe).	Ferrosoferric Oxide	145-154	spindlin 1	Homo sapiens	81-85
34511910-0	2021	Magnetite Fe3O4 Nanoparticles Enhance Mild Microwave Ablation of Tumor by Activating the IRE1-ASK1-JNK Pathway and Inducing Endoplasmic Reticulum Stress.	Ferrosoferric Oxide	0-9	endoplasmic reticulum (ER) to nucleus signalling 2	Mus musculus	89-93
34511910-0	2021	Magnetite Fe3O4 Nanoparticles Enhance Mild Microwave Ablation of Tumor by Activating the IRE1-ASK1-JNK Pathway and Inducing Endoplasmic Reticulum Stress.	Ferrosoferric Oxide	0-9	mitogen-activated protein kinase kinase kinase 5	Mus musculus	94-98
34511910-0	2021	Magnetite Fe3O4 Nanoparticles Enhance Mild Microwave Ablation of Tumor by Activating the IRE1-ASK1-JNK Pathway and Inducing Endoplasmic Reticulum Stress.	Ferrosoferric Oxide	0-9	mitogen-activated protein kinase 8	Mus musculus	99-102
34639075-3	2021	It was shown that the addition of magnetite to an albumin solution at low concentrations of up to 10-6 g/L led to the formation of aggregates with sizes of up to 300 nm in the liquid phase and an increase in the number of spiral structures in the dehydrated films, which indicated an increase in their stability.	Ferrosoferric Oxide	34-43	albumin	Homo sapiens	50-57
34639075-4	2021	With a further increase in the magnetite concentration in the solution (from 10-4 g/L), the magnetic particles stuck together and to albumin, thus forming aggregates with sizes larger than 1000 nm.	Ferrosoferric Oxide	31-40	albumin	Homo sapiens	133-140
34359704-6	2021	Ferumoxytol SPIONs are readily phagocytosed (~104/cell) by the F4/80+CD11b+ TAMs within breast tumors.	Ferrosoferric Oxide	0-11	integrin subunit alpha M	Homo sapiens	69-74
34264055-5	2021	Altering the energetic landscape of magnetite formation by catalyzing the pH-dependent precursor attachment, we tune magnetite nanoparticle size continuously, exceeding sizes observed in magnetotactic bacteria.	Ferrosoferric Oxide	36-45	phenylalanine hydroxylase	Homo sapiens	74-76
34264055-6	2021	This mechanistic shift we uncover here further allows for crystal morphology control by adjusting the pH-dependent interfacial interaction between liquidlike ferrihydrite and nascent magnetite nanoparticles, establishing a new strategy to control nanoparticle morphology.	Ferrosoferric Oxide	183-192	phenylalanine hydroxylase	Homo sapiens	102-104
35413564-4	2022	Later, GR undergoes structural transformation to ferrihydrite and magnetite with the desorption of TBP.	Ferrosoferric Oxide	66-75	TATA-box binding protein	Homo sapiens	99-102
34569962-1	2021	BACKGROUND: The coexistence of magnetite within protein aggregates in the brain is a typical pathologic feature of Alzheimer"s disease (AD), and the formation of amyloid-beta (Abeta) plaques induces critical impairment of cognitive function.	Ferrosoferric Oxide	31-40	amyloid beta (A4) precursor protein	Mus musculus	176-181
35474426-0	2022	Eco-friendly adsorbents based on abietic acid, boswellic acid, and chitosan/magnetite for removing waste oil from the surface of the water.	Ferrosoferric Oxide	76-85	ciliogenesis associated kinase 1	Homo sapiens	0-3
35417136-7	2022	In parallel, ~62% of S2-/Sn2- was released into the solution, with mackinawite transforming into magnetite, Fe(OH)3 and FeS2O3+ complexed to Cl- or OH- species, and magnetite subsequently dispersed in the solution.	Ferrosoferric Oxide	97-106	solute carrier family 38 member 5	Homo sapiens	25-28
35417136-7	2022	In parallel, ~62% of S2-/Sn2- was released into the solution, with mackinawite transforming into magnetite, Fe(OH)3 and FeS2O3+ complexed to Cl- or OH- species, and magnetite subsequently dispersed in the solution.	Ferrosoferric Oxide	165-174	solute carrier family 38 member 5	Homo sapiens	25-28
35314366-12	2022	Moreover, the combination of GCMNPs and ferumoxytol enhanced the blockage of PD-1/PD-L1 to activate T cells, subsequently generating a systemic immune response in CRC and AML mouse models.	Ferrosoferric Oxide	40-51	CD274 molecule	Sus scrofa	82-87
35153018-1	2022	A nanocomposite hydrogel of chitosan/polypropenoic acid/ethylenediamine/magnetite (Cs/PPA/EDA/Fe3O4-NPs) was prepared using a gamma irradiation source (60Co).	Ferrosoferric Oxide	72-81	ectodysplasin A	Homo sapiens	90-93
35131501-7	2022	All synthesized magnetite structures show excellent biocompatibility and minor cytotoxic effects at concentrations up to 1 microg mL-1.	Ferrosoferric Oxide	16-25	L1 cell adhesion molecule	Mus musculus	130-134
35564244-2	2022	Water-saturated column experiments were conducted to investigate the effects of input concentration (Co), ionic strength (IS), and sand grain size on the transport of poly(acrylic acid-co-maleic acid) coated magnetite nanoparticles (PAM@MNP).	Ferrosoferric Oxide	208-217	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	233-236
35044605-1	2022	The purpose of this investigation was to analyze the performance of magnetite graphene oxide modified with beta-cyclodextrin (GO@Fe3O4@beta-CD) for adsorption of methotrexate (MTX) and doxorubicin (DOX) from aqueous solutions.	Ferrosoferric Oxide	68-77	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	135-142
35063763-4	2022	In simulated As(V)-containing solution with initial pH 7.0, zero-valent iron was electrochemically oxidized to magnetite and maghemite at 0.6 V (vs. SCE) for 2 h. The As(V) concentration first decreased from 5127.5 to 26.8 mug L-1 with a removal ratio of 99.5%.	Ferrosoferric Oxide	111-120	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	167-172
33843193-9	2021	The formation of lepidocrocite contributed to the enrichment of Se(VI) on the nZVI surface, and magnetite promoted electron transfer from Fe(0) to Se(VI).	Ferrosoferric Oxide	96-105	squalene epoxidase	Homo sapiens	147-153
16347658-3	1988	GS-15 oxidized acetate to carbon dioxide with the concomitant reduction of amorphic Fe(III) oxide to magnetite (Fe(3)O(4)).	Ferrosoferric Oxide	101-110	Bet1 golgi vesicular membrane trafficking protein like	Homo sapiens	0-5
18548561-1	1983	Rates of glucose oxidation were measured with the use of a fluidized-bed column placed in a magnetic field and magnetite-containing beads of immobilized glucose oxidase and catalase.	Ferrosoferric Oxide	111-120	catalase	Homo sapiens	173-181
35101971-8	2022	This study details the successful labeling of CAR T cells with ferumoxytol, thereby paving the way for monitoring CAR T cells in solid tumors.	Ferrosoferric Oxide	63-74	nuclear receptor subfamily 1 group I member 3	Homo sapiens	46-49
6940148-1	1981	The complete amino acid sequence has been determined for a 50,000-dalton fragment that is an internal segment of the single polypeptide chain of human ceruloplasmin [ferroxidase; iron(II):oxygen oxidoreductase, EC 1.16.3.1].	Ferrosoferric Oxide	179-186	ceruloplasmin	Homo sapiens	151-164
33103961-3	2020	Materials & methods: Herein, we developed a magnetite-based nanomedicine (superparamagnetic iron oxide@poly(sodium styrene sulfonate)/irinotecan/human serum albumin-anti-CD133 nanoparticle) using loco-regional hyperthermia combined with chemotherapy for CRC- and CSC-specific targeting treatment.	Ferrosoferric Oxide	44-53	albumin	Homo sapiens	151-164
34012926-9	2021	Desulfovibrio bacteria produce hydrogen sulfide and lipopolysaccharide, and several strains synthesize magnetite, all of which likely induce the oligomerization and aggregation of alpha-synuclein protein.	Ferrosoferric Oxide	103-112	synuclein alpha	Homo sapiens	180-195
33107799-0	2021	Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer.	Ferrosoferric Oxide	72-83	CD274 antigen	Mus musculus	49-53
33107799-0	2021	Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer.	Ferrosoferric Oxide	72-83	Braf transforming gene	Mus musculus	58-62
32927448-6	2020	Our SERS platform comprises a magnetite core with an intermediate silica shell, and a flower-shaped silver layer (Fe3O4@SiO2@Ag) to confer excellent plasmonic properties and ease of collection by magnetism.	Ferrosoferric Oxide	30-39	seryl-tRNA synthetase 1	Homo sapiens	4-8
33332236-4	2022	Goethite possesses selectivity for Pb(II) and Cu(II), and magnetite possesses selectivity for Pb(II), though the adsorption capacity for the metals are less than those with CR11.	Ferrosoferric Oxide	58-67	submaxillary gland androgen regulated protein 3B	Homo sapiens	94-100
33332236-7	2022	The magnetite is feasible for selective separation of Pb(II), although complete elution cannot be achieved.	Ferrosoferric Oxide	4-13	submaxillary gland androgen regulated protein 3B	Homo sapiens	54-60
33103961-3	2020	Materials & methods: Herein, we developed a magnetite-based nanomedicine (superparamagnetic iron oxide@poly(sodium styrene sulfonate)/irinotecan/human serum albumin-anti-CD133 nanoparticle) using loco-regional hyperthermia combined with chemotherapy for CRC- and CSC-specific targeting treatment.	Ferrosoferric Oxide	44-53	prominin 1	Homo sapiens	170-175
32678736-3	2020	This study showed that the bioreactor amended with magnetite had higher chemical oxygen demand removal efficiencies (90.2% +- 0.54% vs 73.1% +- 1.9%) and methane production rates (4082 +- 334 ml (standard temperature and atmospheric pressure, STP)/d vs 2640 +- 120 ml (STP)/d) than the non-amended control reactor.	Ferrosoferric Oxide	51-60	thyroid hormone receptor interactor 10	Homo sapiens	269-272
33105776-6	2020	The results of low-temperature nitrogen sorption analysis indicated that an increase in the iron(II, III) oxide content leads to a decrease in the BET surface area.	Ferrosoferric Oxide	92-111	putative DNA recombination protein Bet	Escherichia coli	147-150
32917041-3	2020	This study investigated the zeta potentials of magnetite nanoparticles and Alloy 690 surfaces, which were dependent on the pH value, pH agent, and the presence of NaCl.	Ferrosoferric Oxide	47-56	phenylalanine hydroxylase	Homo sapiens	123-125
32678736-3	2020	This study showed that the bioreactor amended with magnetite had higher chemical oxygen demand removal efficiencies (90.2% +- 0.54% vs 73.1% +- 1.9%) and methane production rates (4082 +- 334 ml (standard temperature and atmospheric pressure, STP)/d vs 2640 +- 120 ml (STP)/d) than the non-amended control reactor.	Ferrosoferric Oxide	51-60	thyroid hormone receptor interactor 10	Homo sapiens	243-246
32917041-3	2020	This study investigated the zeta potentials of magnetite nanoparticles and Alloy 690 surfaces, which were dependent on the pH value, pH agent, and the presence of NaCl.	Ferrosoferric Oxide	47-56	phenylalanine hydroxylase	Homo sapiens	133-135
32917041-4	2020	The zeta potentials of the magnetite nanoparticles increased in the negative direction as the pH increased, regardless of the pH agent.	Ferrosoferric Oxide	27-36	phenylalanine hydroxylase	Homo sapiens	94-96
32917041-9	2020	Furthermore, the empirical formulas for the pH-dependent zeta potentials of magnetite particles in each alkaline solution were suggested.	Ferrosoferric Oxide	76-85	phenylalanine hydroxylase	Homo sapiens	44-46
32498824-1	2020	The application of chitosan coated magnetite nanoparticle modified carbon paste electrode as a working electrode (chitosan@Fe3O4/CPE) for Cr(VI) analysis is presented.	Ferrosoferric Oxide	35-44	carboxypeptidase E	Homo sapiens	129-132
32782510-2	2020	The present study prepared stromal cell-derived factor 1 (SDF-1)-loaded, targeted nanoparticles coated with iron (II,III) oxide and perfluorohexane (PFH) to be used as polymer-shelled contrast agents with multimodal imaging functions, with the aim of improving tongue cancer and lymph node metastasis diagnosis.	Ferrosoferric Oxide	108-127	C-X-C motif chemokine ligand 12	Homo sapiens	27-56
32782510-2	2020	The present study prepared stromal cell-derived factor 1 (SDF-1)-loaded, targeted nanoparticles coated with iron (II,III) oxide and perfluorohexane (PFH) to be used as polymer-shelled contrast agents with multimodal imaging functions, with the aim of improving tongue cancer and lymph node metastasis diagnosis.	Ferrosoferric Oxide	108-127	C-X-C motif chemokine ligand 12	Homo sapiens	58-63
32995392-3	2020	In this work we have investigated the adsorption of Pb(II) and Cr(VI) on a nanocomposite that was prepared using magnetite nanoparticles capped with locally prepared biochar and functionalized using 3-(aminopropyl) triethoxysilane (APTES) at 3 different temperatures.	Ferrosoferric Oxide	113-122	submaxillary gland androgen regulated protein 3B	Homo sapiens	52-58
32939177-1	2020	We report the effect of the synthesis route of starch-functionalized magnetite nanoparticles (NPs) on their adsorption properties of As(V) and As(III) from aqueous solutions.	Ferrosoferric Oxide	69-78	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	133-138
32549296-2	2020	This study presents the effects induced by magnetite nanoparticles encapsulated in polymeric micelles (MNP-DSPE-PEG) on biochemical markers, metabolic functions, and MRI signal in CD1 mice liver.	Ferrosoferric Oxide	43-52	modifier of Niemann Pick type C1	Mus musculus	103-106
32632229-3	2020	Treatment of the animals with anti-erythrocyte antibodies significantly improved the targeting of CD4+ cells in vivo with fluorescent anti-CD4-antibody-conjugated nanoparticles, the magnetically guided delivery of ferrofluid nanoparticles to subcutaneous tumour allografts and xenografts, and the treatment of subcutaneous tumour allografts with magnetically guided liposomes loaded with doxorubicin and magnetite or with clinically approved "stealthy" doxorubicin liposomes.	Ferrosoferric Oxide	404-413	CD4 antigen	Mus musculus	98-101
32632229-3	2020	Treatment of the animals with anti-erythrocyte antibodies significantly improved the targeting of CD4+ cells in vivo with fluorescent anti-CD4-antibody-conjugated nanoparticles, the magnetically guided delivery of ferrofluid nanoparticles to subcutaneous tumour allografts and xenografts, and the treatment of subcutaneous tumour allografts with magnetically guided liposomes loaded with doxorubicin and magnetite or with clinically approved "stealthy" doxorubicin liposomes.	Ferrosoferric Oxide	404-413	CD4 antigen	Mus musculus	139-142
32549296-2	2020	This study presents the effects induced by magnetite nanoparticles encapsulated in polymeric micelles (MNP-DSPE-PEG) on biochemical markers, metabolic functions, and MRI signal in CD1 mice liver.	Ferrosoferric Oxide	43-52	CD1 antigen complex	Mus musculus	180-183
32170399-1	2020	Synthesis and functionalization of magnetite nanoparticles (Fe3O4) was achieved with the view to covalently bind both cholesterol oxidase and cholesterol esterase biorecognition agents for the development of free and total cholesterol biosensors.	Ferrosoferric Oxide	35-44	carboxyl ester lipase	Homo sapiens	142-162
32028168-8	2020	This finding clearly indicated the intracellular localization of ferumoxytol at 24 h, as confirmed by histological analysis (Pearls and CD68 assays).	Ferrosoferric Oxide	65-76	CD68 antigen	Mus musculus	136-140
32301466-6	2020	The interaction of interleukin 6 with the antibodies produces a blue-shift in resonant wavelength and the reflectance intensity increases up to 50% and 44% when tested with CoF & magnetite based MPC respectively at a concentration of 50 pg ml-1.	Ferrosoferric Oxide	179-188	interleukin 6	Homo sapiens	19-32
31866569-2	2020	In the present study, we show that two clinically used IONPs, ferumoxytol and ferucarbotran, have an intrinsic inhibitory effect on receptor activator NF-kappaB ligand (RANKL)-induced osteoclastogenesis of bone marrow-derived monocytes/macrophages (BMMs).	Ferrosoferric Oxide	62-73	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	132-167
31866569-2	2020	In the present study, we show that two clinically used IONPs, ferumoxytol and ferucarbotran, have an intrinsic inhibitory effect on receptor activator NF-kappaB ligand (RANKL)-induced osteoclastogenesis of bone marrow-derived monocytes/macrophages (BMMs).	Ferrosoferric Oxide	62-73	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	169-174
31844996-8	2019	Moreover, FMT significantly downregulated the expression levels of Arg-1, S100A8, S100A9, and p47phox as well as ROS production in MDSCs.	Ferrosoferric Oxide	10-13	arginase, liver	Mus musculus	67-72
31726340-3	2020	This study developed a new class of polyacrylamide-dispersed magnetite (PAM-MAG) nanoparticles and tested the effectiveness for simultaneous control of soil erosion and arsenic leaching from a model soil.	Ferrosoferric Oxide	61-70	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	72-75
31726340-6	2020	A stable dispersion of PAM-MAG was prepared with 0.3 wt% of PAM and 0.1 g/L as Fe of magnetite.	Ferrosoferric Oxide	85-94	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	23-26
32010098-8	2019	Especially magnetite triggered substantial Fe-AOM activity and caused an enrichment of ANME-2a archaea.	Ferrosoferric Oxide	11-20	collagen type II alpha 1 chain	Homo sapiens	43-49
31910856-0	2020	Ultrasensitive haptoglobin biomarker detection based on amplified chemiluminescence of magnetite nanoparticles.	Ferrosoferric Oxide	87-96	haptoglobin	Bos taurus	15-26
31844996-8	2019	Moreover, FMT significantly downregulated the expression levels of Arg-1, S100A8, S100A9, and p47phox as well as ROS production in MDSCs.	Ferrosoferric Oxide	10-13	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	74-80
31844996-8	2019	Moreover, FMT significantly downregulated the expression levels of Arg-1, S100A8, S100A9, and p47phox as well as ROS production in MDSCs.	Ferrosoferric Oxide	10-13	S100 calcium binding protein A9 (calgranulin B)	Mus musculus	82-88
31844996-8	2019	Moreover, FMT significantly downregulated the expression levels of Arg-1, S100A8, S100A9, and p47phox as well as ROS production in MDSCs.	Ferrosoferric Oxide	10-13	neutrophil cytosolic factor 1	Mus musculus	94-101
31844996-13	2019	Expectedly, FMT also significantly reduced Arg-1 and p47phox gene expression in splenic CD11b+Gr-1+ cells isolated from LPS-challenged mice.	Ferrosoferric Oxide	12-15	arginase 1	Homo sapiens	43-48
31844996-13	2019	Expectedly, FMT also significantly reduced Arg-1 and p47phox gene expression in splenic CD11b+Gr-1+ cells isolated from LPS-challenged mice.	Ferrosoferric Oxide	12-15	neutrophil cytosolic factor 1	Homo sapiens	53-60
31844996-13	2019	Expectedly, FMT also significantly reduced Arg-1 and p47phox gene expression in splenic CD11b+Gr-1+ cells isolated from LPS-challenged mice.	Ferrosoferric Oxide	12-15	integrin subunit alpha M	Homo sapiens	88-93
31844996-14	2019	These data indicate that FMT decreased the immunosuppressive functions of MDSCs by decreasing Arg-1 and ROS production, suggesting that FMT may reduce long-term immunosuppression in the late stage of sepsis.	Ferrosoferric Oxide	25-28	arginase, liver	Mus musculus	94-99
31844996-14	2019	These data indicate that FMT decreased the immunosuppressive functions of MDSCs by decreasing Arg-1 and ROS production, suggesting that FMT may reduce long-term immunosuppression in the late stage of sepsis.	Ferrosoferric Oxide	136-139	arginase, liver	Mus musculus	94-99
31697069-0	2019	Correction to "Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells".	Ferrosoferric Oxide	39-48	LCS1	Homo sapiens	98-103
31623127-3	2019	For this reason, we developed optimized multicore particles (MCP 3) made by coprecipitation via synthesis of green rust and subsequent oxidation to iron oxide cores consisting of a magnetite/maghemite mixed phase.	Ferrosoferric Oxide	181-190	C-C motif chemokine ligand 7	Homo sapiens	61-66
30739714-2	2019	In this study, we demonstrate co-immobilization of xylose dehydrogenase (XDH, EC 1.1.1.175) and alcohol dehydrogenase (ADH, EC 1.1.1.1) using magnetite-silica core-shell particles for simultaneous conversion of xylose into xylonic acid (XA) and in situ cofactor regeneration.	Ferrosoferric Oxide	142-151	xanthine dehydrogenase	Homo sapiens	51-71
30739714-2	2019	In this study, we demonstrate co-immobilization of xylose dehydrogenase (XDH, EC 1.1.1.175) and alcohol dehydrogenase (ADH, EC 1.1.1.1) using magnetite-silica core-shell particles for simultaneous conversion of xylose into xylonic acid (XA) and in situ cofactor regeneration.	Ferrosoferric Oxide	142-151	xanthine dehydrogenase	Homo sapiens	73-76
31691866-0	2019	Competitive aptasensor with gold nanoparticle dimers and magnetite nanoparticles for SERS-based determination of thrombin.	Ferrosoferric Oxide	57-66	coagulation factor II, thrombin	Homo sapiens	113-121
31697036-1	2019	Herein, ferumoxytol (Fer) capped antiprogrammed cell death-ligand 1 (PD-L1) antibodies (aPD-L1) loaded ultralarge pore mesoporous silica nanoparticles (Fer-ICB-UPMSNPs) are formulated for a sequential magnetic resonance (MR) image guided local immunotherapy after cabazitaxel (Cbz) chemotherapy for the treatment of prostate cancer (PC).	Ferrosoferric Oxide	8-19	CD274 molecule	Homo sapiens	69-74
31697036-1	2019	Herein, ferumoxytol (Fer) capped antiprogrammed cell death-ligand 1 (PD-L1) antibodies (aPD-L1) loaded ultralarge pore mesoporous silica nanoparticles (Fer-ICB-UPMSNPs) are formulated for a sequential magnetic resonance (MR) image guided local immunotherapy after cabazitaxel (Cbz) chemotherapy for the treatment of prostate cancer (PC).	Ferrosoferric Oxide	21-24	CD274 molecule	Homo sapiens	69-74
31027039-0	2019	Synthesis of MOR Zeolite/Magnetite Composite via Seed Assisted Method.	Ferrosoferric Oxide	25-34	opioid receptor mu 1	Homo sapiens	13-16
31027039-6	2019	MOR zeolite/magnetite composite with high MOR zeolite crystallinity was obtained by synthesizing for only 6 hours at 463 K when adding seed crystals, while no sign of crystallization was observed even after 24 hours in their absence.	Ferrosoferric Oxide	12-21	opioid receptor mu 1	Homo sapiens	42-45
31027039-5	2019	In this work, we selected magnetite as the magnetic particle and propose the hydrothermal synthesis of MOR zeolite/magnetite composite via seed assisted method for the first time.	Ferrosoferric Oxide	26-35	opioid receptor mu 1	Homo sapiens	103-106
31027039-7	2019	In addition, pre-milling of seed crystals together with magnetite was found to be effective to incorporate magnetite into MOR zeolite during crystallization and to decrease the primary crystal size of the crystallized MOR zeolite.	Ferrosoferric Oxide	56-65	opioid receptor mu 1	Homo sapiens	122-125
31027039-7	2019	In addition, pre-milling of seed crystals together with magnetite was found to be effective to incorporate magnetite into MOR zeolite during crystallization and to decrease the primary crystal size of the crystallized MOR zeolite.	Ferrosoferric Oxide	56-65	opioid receptor mu 1	Homo sapiens	218-221
31027039-5	2019	In this work, we selected magnetite as the magnetic particle and propose the hydrothermal synthesis of MOR zeolite/magnetite composite via seed assisted method for the first time.	Ferrosoferric Oxide	115-124	opioid receptor mu 1	Homo sapiens	103-106
31027039-7	2019	In addition, pre-milling of seed crystals together with magnetite was found to be effective to incorporate magnetite into MOR zeolite during crystallization and to decrease the primary crystal size of the crystallized MOR zeolite.	Ferrosoferric Oxide	107-116	opioid receptor mu 1	Homo sapiens	122-125
31027039-6	2019	MOR zeolite/magnetite composite with high MOR zeolite crystallinity was obtained by synthesizing for only 6 hours at 463 K when adding seed crystals, while no sign of crystallization was observed even after 24 hours in their absence.	Ferrosoferric Oxide	12-21	opioid receptor mu 1	Homo sapiens	0-3
30880516-0	2019	Application of luteinizing hormone-releasing hormone-ferrosoferric oxide nanoparticles in targeted imaging of breast tumors.	Ferrosoferric Oxide	53-72	gonadotropin releasing hormone 1	Homo sapiens	15-52
30764944-0	2019	Organic/Inorganic Fe3O4@MCM-41@Zr-Piperazine: An Impressive Magnetite Nanocatalyst for N-Tert-Butoxycarbonylation of Amines.	Ferrosoferric Oxide	60-69	telomerase reverse transcriptase	Homo sapiens	89-93
30802204-10	2019	The mean change in hemoglobin in the ferumoxytol and iron sucrose groups was 0.5 and 0.4 g/dL, respectively, in TP 1 (least-squares mean difference, 0.13; 95% confidence interval, -0.11 to 0.36) and 0.6 and 0.3 g/dL, respectively, in TP 2 (0.30; 0.06 - 0.55).	Ferrosoferric Oxide	37-48	transition protein 1	Homo sapiens	112-116
30802204-10	2019	The mean change in hemoglobin in the ferumoxytol and iron sucrose groups was 0.5 and 0.4 g/dL, respectively, in TP 1 (least-squares mean difference, 0.13; 95% confidence interval, -0.11 to 0.36) and 0.6 and 0.3 g/dL, respectively, in TP 2 (0.30; 0.06 - 0.55).	Ferrosoferric Oxide	37-48	transition protein 2	Homo sapiens	234-238
31443385-0	2019	Chondroitin-Sulfate-A-Coated Magnetite Nanoparticles: Synthesis, Characterization and Testing to Predict Their Colloidal Behavior in Biological Milieu.	Ferrosoferric Oxide	29-38	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	0-21
31417255-6	2019	Then, the effects of FMT/CpG-pretreated MPhi supernatant on apoptosis and proliferation of H1975 cells were detected by flow cytometry, and the expression of EGFR and its downstream signaling pathway in H1975 cells were explored by western blotting.	Ferrosoferric Oxide	21-24	epidermal growth factor receptor	Homo sapiens	158-162
31151258-2	2019	Herein, we report on the synthesis of PANI composites with magnetic oxide (Fe3O4) for efficient removal of Basic Blue 3 (BB3) dye from aqueous solution.	Ferrosoferric Oxide	59-73	bombesin receptor subtype 3	Homo sapiens	107-124
31163762-2	2019	Stable mode-locked operation can be conveniently achieved based on the interaction between Ex-TFG coupled light and deposited ferroferric-oxide (Fe3O4) nanoparticles.	Ferrosoferric Oxide	126-143	trafficking from ER to golgi regulator	Homo sapiens	94-97
31193134-3	2019	The adsorption capacity of the magnetite was highly dependent on pH value, for Cd+2, Zn+2, Ni+2 and Cu+2 the removal performance was higher that 80% at pH = 8.	Ferrosoferric Oxide	31-40	CD2 molecule	Homo sapiens	79-83
30860371-6	2019	Therefore, we hypothesized that ferumoxytol particles functionalized with VEGF-165 will accumulate in ischemic myocardial regions and can be detected by MRI, while the prolonged retention of VEGF-165 due to ferumoxytol-coupling will help to prevent adverse tissue remodeling.	Ferrosoferric Oxide	32-43	vascular endothelial growth factor A	Homo sapiens	74-78
30674867-4	2019	We evaluated if ferumoxytol-enhanced MRI can monitor TAM response to CD47 mAb therapy in osteosarcomas.	Ferrosoferric Oxide	16-27	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	69-73
30678949-0	2019	Silver nanoparticles decorated on thiol-modified magnetite nanoparticles (Fe3O4/SiO2-Pr-S-Ag) as a recyclable nanocatalyst for degradation of organic dyes.	Ferrosoferric Oxide	49-58	S-antigen visual arrestin	Homo sapiens	88-92
30904972-12	2019	Graphical abstract Schematic presentation of polyamidoamine (PAMAM) dendrimers modified magnetite (Fe3O4) nanoparticles as electrochemical sensing platform using redox dyes Prussian blue and toluidine blue for simultaneous detection of alpha-fetoprotein (AFP) and glypican-3 (GPC-3), respectively by differential pulse voltammetry.	Ferrosoferric Oxide	88-97	alpha fetoprotein	Homo sapiens	236-253
30904972-12	2019	Graphical abstract Schematic presentation of polyamidoamine (PAMAM) dendrimers modified magnetite (Fe3O4) nanoparticles as electrochemical sensing platform using redox dyes Prussian blue and toluidine blue for simultaneous detection of alpha-fetoprotein (AFP) and glypican-3 (GPC-3), respectively by differential pulse voltammetry.	Ferrosoferric Oxide	88-97	alpha fetoprotein	Homo sapiens	255-258
30904972-12	2019	Graphical abstract Schematic presentation of polyamidoamine (PAMAM) dendrimers modified magnetite (Fe3O4) nanoparticles as electrochemical sensing platform using redox dyes Prussian blue and toluidine blue for simultaneous detection of alpha-fetoprotein (AFP) and glypican-3 (GPC-3), respectively by differential pulse voltammetry.	Ferrosoferric Oxide	88-97	glypican 3	Homo sapiens	264-274
30904972-12	2019	Graphical abstract Schematic presentation of polyamidoamine (PAMAM) dendrimers modified magnetite (Fe3O4) nanoparticles as electrochemical sensing platform using redox dyes Prussian blue and toluidine blue for simultaneous detection of alpha-fetoprotein (AFP) and glypican-3 (GPC-3), respectively by differential pulse voltammetry.	Ferrosoferric Oxide	88-97	glypican 3	Homo sapiens	276-281
30765836-4	2019	Magnetite nanoparticles carrying the complementary sequence of miR-198 (miR-198 antisense) on their surface were delivered into cells and subsequently used for the extracellular transport of miRNA and proteins.	Ferrosoferric Oxide	0-9	microRNA 198	Homo sapiens	63-70
30765836-4	2019	Magnetite nanoparticles carrying the complementary sequence of miR-198 (miR-198 antisense) on their surface were delivered into cells and subsequently used for the extracellular transport of miRNA and proteins.	Ferrosoferric Oxide	0-9	microRNA 198	Homo sapiens	72-79
30674867-8	2019	Compared to IgG-treated controls, CD47 mAb-treated tumors demonstrated significantly shortened T2 relaxation times on ferumoxytol-MRI scans (p < 0.01) and significantly increased F4/80+CD80+ M1 macrophages on histopathology (p < 0.01).	Ferrosoferric Oxide	118-129	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	34-38
30674867-9	2019	CD47 mAb-treated F4/80+ macrophages demonstrated significantly augmented phagocytosis of ferumoxytol nanoparticles (p < 0.01).	Ferrosoferric Oxide	89-100	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	0-4
30583315-1	2018	Immobilization of CD34 antibody on ferroferric oxide magnetic nanoparticles was achieved by the traditional carboxyl-amine conjugation reaction.	Ferrosoferric Oxide	35-52	CD34 molecule	Homo sapiens	18-22
30674867-9	2019	CD47 mAb-treated F4/80+ macrophages demonstrated significantly augmented phagocytosis of ferumoxytol nanoparticles (p < 0.01).	Ferrosoferric Oxide	89-100	adhesion G protein-coupled receptor E1	Mus musculus	17-22
30674867-10	2019	Thus, we conclude that ferumoxytol-MRI can detect TAM response to CD47 mAb in mouse models of osteosarcoma.	Ferrosoferric Oxide	23-34	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	66-70
29451980-0	2018	Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells.	Ferrosoferric Oxide	24-33	LCS1	Homo sapiens	83-88
30366475-3	2018	The magnetite nanoparticles were incorporated into Na-VS/Na-AMPS cryogel networks either during its crosslinking polymerization or by the in-situ technique after its crosslinking.	Ferrosoferric Oxide	4-13	adenylosuccinate lyase	Homo sapiens	60-64
28699008-1	2018	Magnetite (Fe3O4) nanoparticle-encapsulated mesoporous carbon nanocomposite was fabricated from Fe-based metal-organic framework (MOF) (MIL-102) through carbonization.	Ferrosoferric Oxide	0-9	lysine acetyltransferase 8	Homo sapiens	105-134
30299938-4	2018	Herein, we report a novel nanocomposite prepared by heparin-mediated cross-linking of urokinase with magnetite nanoparticles (MNPs@uPA).	Ferrosoferric Oxide	101-110	plasminogen activator, urokinase	Rattus norvegicus	131-134
29764855-10	2018	Within each tumor group, T2* signal enhancement on MR images correlated significantly with the density of CD68+ and CD163+ TAM (P < 0.05).Conclusions: Ferumoxytol-enhanced MRI is immediately clinically applicable and could be used to stratify patients with TAM-rich tumors to immune-targeted therapies and to monitor tumor response to these therapies.	Ferrosoferric Oxide	154-165	CD68 molecule	Homo sapiens	106-110
29977742-5	2018	Methods: We used a customized caspase-3 cleavable peptide-dye conjugate to modify the surface of clinically approved ferumoxytol nanoparticles (NPs) to generate the dual-modality imaging probe with fluorescence "light-up" feature.	Ferrosoferric Oxide	117-128	caspase 3	Mus musculus	30-39
28499172-0	2017	Fluorescence quenching study on the interaction of ferroferric oxide nanoparticles with bovine serum albumin.	Ferrosoferric Oxide	51-68	albumin	Homo sapiens	95-108
29319081-2	2018	The magnetic oxide substrate locks the [Fe{H2B(pz)2}2(bipy)] largely in a low spin state.	Ferrosoferric Oxide	4-18	H2B clustered histone 21	Homo sapiens	43-46
28774792-7	2017	Ferumoxytol uptake in CD68-positive cells was observed in the cerebral arterial walls of 4 out of 15 (26.7%) experimentally induced aneurysms in rats.	Ferrosoferric Oxide	0-11	Cd68 molecule	Rattus norvegicus	22-26
29448754-1	2018	Recyclable magnetites with thioureido group (poly-allyl-thiourea/oleic acid/magnetite, PAT-adsorbent) and amine functional group (ethylenediamine/methyl methacrylate/oleic acid/magnetite, EDA-adsorbent) were synthesized by modifying magnetite with oleic acid, methyl methacrylate, allyl thiourea and ethylenediamine.	Ferrosoferric Oxide	11-20	ectodysplasin A	Homo sapiens	188-191
29091852-4	2018	Scanning electron microscope (SEM), nitrogen adsorption, Fourier transform infrared spectroscopy (FTIR) and microbial analysis indicated that magnetite enriched iron-reducing bacteria responsible for sludge hydrolysis while GAC enhanced syntrophic metabolism between iron-reducing bacteria and methanogens due to its high electrical conductivity and large surface area.	Ferrosoferric Oxide	142-151	glutaminase	Homo sapiens	224-227
28499172-1	2017	Fluorescence quenching was used to study the potential interaction mechanism of Bovine serum albumin (BSA) with either hydrophilic ferroferric oxide (Fe3O4) nanoparticles (NPs) or hydrophobic Fe3O4 NPs.	Ferrosoferric Oxide	131-148	albumin	Homo sapiens	87-100
28128708-6	2017	Macrophages of Jax C57BL/6-Tg (Csf1r-EGFP-NGFR/FKBP1A/TNFRSF6) 2Bck/J mice express enhanced green fluorescent protein (GFP), which enables in vivo correlation of ferumoxytol enhancement at MR imaging with macrophage quantities at IVM.	Ferrosoferric Oxide	162-173	colony stimulating factor 1 receptor	Mus musculus	31-36
28726714-3	2017	The experimental results showed that at the optimum doses of 20 mg L-1 ferric chloride (FeCl3), 4 mg L-1 magnetite (Fe3O4) and 6 mg L-1 reclaimed magnetic flocs in RMFMF processes, removal efficiencies of above evaluated parameters ranged from 55.8% to 92.9%, which performed best.	Ferrosoferric Oxide	105-114	immunoglobulin kappa variable 1-16	Homo sapiens	101-104
28750536-0	2017	Magnetite-Quantum Dot Immunoarray for Plasmon-Coupled-Fluorescence Imaging of Blood Insulin and Glycated Hemoglobin.	Ferrosoferric Oxide	0-9	insulin	Homo sapiens	84-91
28726714-3	2017	The experimental results showed that at the optimum doses of 20 mg L-1 ferric chloride (FeCl3), 4 mg L-1 magnetite (Fe3O4) and 6 mg L-1 reclaimed magnetic flocs in RMFMF processes, removal efficiencies of above evaluated parameters ranged from 55.8% to 92.9%, which performed best.	Ferrosoferric Oxide	105-114	immunoglobulin kappa variable 1-16	Homo sapiens	101-104
27668795-3	2016	In vitro, adenocarcinoma cells co-incubated with ferumoxytol and macrophages showed increased caspase-3 activity.	Ferrosoferric Oxide	49-60	caspase 3	Mus musculus	94-103
27940247-11	2017	MRI with ferumoxytol as a contrast agent noninvasively demonstrated macrophage reduction in OLA-PEG + anti-VEGF-treated rats compared with VEGF blockade alone.	Ferrosoferric Oxide	9-20	vascular endothelial growth factor A	Rattus norvegicus	107-111
27611357-3	2016	The results showed that 40mgL-1 of powdered magnetite and hematite addition decreased the sulfide in sewage by 79%and 70%, respectively.	Ferrosoferric Oxide	44-53	LLGL scribble cell polarity complex component 1	Homo sapiens	26-31
27773281-1	2017	Magnetite (Fe3O4 nanoparticles (NPs)) HKUST-1 metal organic framework (MOF) composite as a support was used for surface imprinting of gallic acid imprinted polymer (HKUST-1-MOF-Fe3O4-GA-MIP) using vinyltrimethoxysilane (VTMOS) as the cross-linker.	Ferrosoferric Oxide	0-9	lysine acetyltransferase 8	Homo sapiens	71-74
27773281-1	2017	Magnetite (Fe3O4 nanoparticles (NPs)) HKUST-1 metal organic framework (MOF) composite as a support was used for surface imprinting of gallic acid imprinted polymer (HKUST-1-MOF-Fe3O4-GA-MIP) using vinyltrimethoxysilane (VTMOS) as the cross-linker.	Ferrosoferric Oxide	0-9	lysine acetyltransferase 8	Homo sapiens	165-176
27775147-1	2016	The mechanisms for the reduction and uptake of Tc by magnetite (Fe3O4) and mackinawite (FeS) are investigated using X-ray absorption spectroscopy (XANES and EXAFS), in combination with thermodynamic calculations of the Tc/Fe systems and accurate characterization of the solution properties (pHm, pe, [Tc]).	Ferrosoferric Oxide	53-62	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	291-294
26686923-1	2016	A sandwich-type electrochemical immunosensor was developed for sensitive detection of carcinoembryonic antigen (CEA) by using ferroferric oxide@silica-amino groups (Fe3O4@SiO2-NH2) as carriers and gold nanoparticles-graphene oxide (GO-AuNPs) as platform.	Ferrosoferric Oxide	126-143	CEA cell adhesion molecule 3	Homo sapiens	86-110
27542738-5	2016	The results indicated that immunoassays incorporating the magnetite suspension-based washing method are effective for medical diagnoses based on CRP assay.	Ferrosoferric Oxide	58-67	catabolite gene activator protein	Escherichia coli	145-148
27704352-1	2016	We synthesized a fluorescence conjugate and modified magnetite-gold nanoparticles carrying prostate specific membrane antigen (PSMA) as the ligand.	Ferrosoferric Oxide	53-62	folate hydrolase 1	Homo sapiens	91-125
27704352-1	2016	We synthesized a fluorescence conjugate and modified magnetite-gold nanoparticles carrying prostate specific membrane antigen (PSMA) as the ligand.	Ferrosoferric Oxide	53-62	folate hydrolase 1	Homo sapiens	127-131
27071335-5	2016	We found that ferumoxytol nanoparticles were taken up by astrocyte endfeet surrounding cerebral vessels, astrocyte processes, and CD163(+)/CD68(+) macrophages, but not by tumor cells.	Ferrosoferric Oxide	14-25	CD163 molecule	Homo sapiens	130-135
26686923-1	2016	A sandwich-type electrochemical immunosensor was developed for sensitive detection of carcinoembryonic antigen (CEA) by using ferroferric oxide@silica-amino groups (Fe3O4@SiO2-NH2) as carriers and gold nanoparticles-graphene oxide (GO-AuNPs) as platform.	Ferrosoferric Oxide	126-143	CEA cell adhesion molecule 3	Homo sapiens	112-115
25854197-0	2015	Magnetic/NIR-responsive drug carrier, multicolor cell imaging, and enhanced photothermal therapy of gold capped magnetite-fluorescent carbon hybrid nanoparticles.	Ferrosoferric Oxide	112-121	NOC2 like nucleolar associated transcriptional repressor	Mus musculus	9-12
26797949-7	2016	New magnetite (Fe3O4) produced by the redox reaction of NO3 (-) and Fe(0) was discovered on the surface of the Fe(0) obtained from L2.	Ferrosoferric Oxide	4-13	NBL1, DAN family BMP antagonist	Homo sapiens	56-59
26551223-0	2016	Comparative evaluation of magnetite-graphene oxide and magnetite-reduced graphene oxide composite for As(III) and As(V) removal.	Ferrosoferric Oxide	55-64	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	114-119
26750752-7	2016	This preclinical study indicates that ILK-engineered MSCs might promote the clinical translation of MSC-based therapy in post-MI patients, and provides evidence that ferumoxytol labeling of cells combined with PLL is feasible in in vivo cell tracking.	Ferrosoferric Oxide	166-177	integrin linked kinase	Homo sapiens	38-41
26501808-11	2015	CONCLUSIONS: A single ferumoxytol dose can affect measured SUV for at least 3 months, which should be taken into account when administrating ferumoxytol in patients needing sequential PET/MR scans.	Ferrosoferric Oxide	22-33	ATPase, class II, type 9B	Mus musculus	188-190
26154495-7	2015	The local magnetic field inherent of magnetite particles present on the surface of XCA/mag facilitates synapse formation, because synaptophysin expression and electrical transmission were increased when compared to the other scaffolds used.	Ferrosoferric Oxide	37-46	X chromosome controlling element	Homo sapiens	83-86
26154495-7	2015	The local magnetic field inherent of magnetite particles present on the surface of XCA/mag facilitates synapse formation, because synaptophysin expression and electrical transmission were increased when compared to the other scaffolds used.	Ferrosoferric Oxide	37-46	synaptophysin	Homo sapiens	130-143
25050519-7	2015	Nitrotyrosine and caspase 3 levels were significantly (p<0.01) increased in all assessed organs of animals treated with iron dextran and iron isomaltoside 1000, as well as in the liver and kidneys of ferumoxytol-treated animals compared to isotonic saline solution (control).	Ferrosoferric Oxide	203-214	caspase 3	Rattus norvegicus	18-27
25050519-8	2015	Nitrotyrosine and caspase 3 levels were shown to correlate positively with the amount of Prussian blue-detectable iron(III) deposits in iron dextran- and iron isomaltoside 1000-treated rats but not in ferumoxytol-treated rats, suggesting that iron dextran, iron isomaltoside 1000 and ferumoxytol induce nitrosative (and oxidative) stress as well as apoptosis via different mechanism(s).	Ferrosoferric Oxide	284-295	caspase 3	Rattus norvegicus	18-27
26501808-13	2015	Ferumoxytol aggregates, but not ferumoxytol alone, produce significant artifacts in MR-derived attenuation correction maps at approximate clinical dose levels of 10 mg/kg.	Ferrosoferric Oxide	0-11	ATPase, class II, type 9B	Mus musculus	84-86
26501808-15	2015	When performing simultaneous whole-body (18)F-FDG PET/MR, a single dose of ferumoxytol can result in observed SUV decreases up to 53%, depending on the amount of ferumoxytol aggregates in the studied tissue.	Ferrosoferric Oxide	75-86	ATPase, class II, type 9B	Mus musculus	54-56
26501808-16	2015	Implications for patient care Administration of a single, clinically relevant, dose of ferumoxytol can potentially result in changes in observed SUV for a prolonged period of time in the setting of simultaneous PET/MR.	Ferrosoferric Oxide	87-98	ATPase, class II, type 9B	Mus musculus	215-217
26501808-17	2015	These potential changes should be considered in particular when administering ferumoxytol to patients with expected future PET/MR studies, as ferumoxytol-induced SUV changes might interfere with therapy assessment.	Ferrosoferric Oxide	78-89	ATPase, class II, type 9B	Mus musculus	127-129
26501808-17	2015	These potential changes should be considered in particular when administering ferumoxytol to patients with expected future PET/MR studies, as ferumoxytol-induced SUV changes might interfere with therapy assessment.	Ferrosoferric Oxide	142-153	ATPase, class II, type 9B	Mus musculus	127-129
25590823-7	2015	During the dissolution, secondary minerals such as goethite, magnetite and FeS were detected and played different roles in the mobilization of As(V).	Ferrosoferric Oxide	61-70	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	143-148
25565814-0	2015	Ferroferric oxide nanoparticles induce prosurvival autophagy in human blood cells by modulating the Beclin 1/Bcl-2/VPS34 complex.	Ferrosoferric Oxide	0-17	beclin 1	Homo sapiens	100-108
25590823-8	2015	The released As(V) was mainly repartitioned on the residual ferrihydrite, the newly-formed goethite and magnetite but not FeS.	Ferrosoferric Oxide	104-113	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	13-18
25791354-0	2015	Synthesis of magnetite-graphene oxide-layered double hydroxide composites and applications for the removal of Pb(II) and 2,4-dichlorophenoxyacetic acid from aqueous solutions.	Ferrosoferric Oxide	13-22	submaxillary gland androgen regulated protein 3B	Homo sapiens	110-116
25675332-5	2015	This detection limit was further lowered to 5 pM by designing serum insulin conjugates with poly(acrylic acid)-functionalized magnetite nanoparticles (100 nm hydrodynamic diameter) and detecting the binding of MNP-serum insulin conjugate to the surface insulin-antibody on PGE/MWNT/Py electrodes.	Ferrosoferric Oxide	126-135	insulin	Homo sapiens	68-75
25565814-0	2015	Ferroferric oxide nanoparticles induce prosurvival autophagy in human blood cells by modulating the Beclin 1/Bcl-2/VPS34 complex.	Ferrosoferric Oxide	0-17	BCL2 apoptosis regulator	Homo sapiens	109-114
25565814-0	2015	Ferroferric oxide nanoparticles induce prosurvival autophagy in human blood cells by modulating the Beclin 1/Bcl-2/VPS34 complex.	Ferrosoferric Oxide	0-17	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	115-120
25924407-4	2014	The substitution of chromium greatly increased the BET specific surface area and surface hydroxyl amount, which improved the heterogeneous UV/Fenton catalytic activity of magnetite.	Ferrosoferric Oxide	171-180	delta/notch like EGF repeat containing	Homo sapiens	51-54
25375144-0	2014	Magnetite nanoparticles inhibit tumor growth and upregulate the expression of p53/p16 in Ehrlich solid carcinoma bearing mice.	Ferrosoferric Oxide	0-9	transformation related protein 53, pseudogene	Mus musculus	78-81
25375144-0	2014	Magnetite nanoparticles inhibit tumor growth and upregulate the expression of p53/p16 in Ehrlich solid carcinoma bearing mice.	Ferrosoferric Oxide	0-9	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	82-85
24315802-6	2014	The ability of ferumoxytol to maintain hemoglobin (Hb), transferrin saturation (TSAT), and ferritin treatment targets established by the 2006 Kidney Disease Outcomes Quality Initiative guidelines was determined in 3 medium-sized US-based dialysis chains.	Ferrosoferric Oxide	15-26	transferrin	Homo sapiens	56-67
24863781-1	2014	In this study, a series of Mn substituted magnetites were synthesized and used in catalyzing the heterogeneous Fenton degradation of acid orange II and Pb(II) adsorption, in order to investigate the effect of Mn substitution on the reactivity of magnetite.	Ferrosoferric Oxide	42-51	submaxillary gland androgen regulated protein 3B	Homo sapiens	152-158
24863781-7	2014	The adsorption capacity of magnetite samples toward Pb(II) gradually increased with the increase in Mn content.	Ferrosoferric Oxide	27-36	submaxillary gland androgen regulated protein 3B	Homo sapiens	52-58
24584068-1	2014	This study investigated effectiveness of starch-stabilized magnetite nanoparticles for in situ enhanced sorption and immobilization of arsenate, As(V), in a model sandy loam soil.	Ferrosoferric Oxide	59-68	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	145-150
24963410-2	2014	Silica-coated magnetite NPs were prepared by sol-gel reaction, subsequently coated with 3-aminopropyltriethoxysilane (APTES) via silanization reaction, and then were activated with 2,4,6-trichloro-1,3,5-triazine (TCT) and covalently immobilized with bovine serum albumin (BSA).	Ferrosoferric Oxide	14-23	albumin	Homo sapiens	257-270
24252617-0	2013	Thiol-functionalized magnetite/graphene oxide hybrid as a reusable adsorbent for Hg2+ removal.	Ferrosoferric Oxide	21-30	polycystin 1, transient receptor potential channel interacting pseudogene 2	Homo sapiens	81-84
24129909-2	2013	Four HIV-infected subjects with undetectable HIV RNA levels on antiretroviral therapy, HIV DNA level in CD14+ cells >=10 copies/10(6) cells, and cognitive impairment underwent ferumoxytol-enhanced brain MRI.	Ferrosoferric Oxide	179-190	CD14 molecule	Homo sapiens	104-108
24252617-1	2013	A thiol-functionalized magnetite/graphene oxide (MGO) hybrid as an adsorbent of Hg2+ was successfully synthesized by a two-step reaction.	Ferrosoferric Oxide	23-32	polycystin 1, transient receptor potential channel interacting pseudogene 2	Homo sapiens	80-83
23533767-4	2013	Magnetite nanoparticles were conjugated with NPrCAP to introduce thermotherapeutic and immunotherapeutic effects through nonapoptotic cell death and generation of heat shock protein (HSP) upon exposure to alternating magnetic field (AMF).	Ferrosoferric Oxide	0-9	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	163-181
23819021-3	2013	Herein we present a systematic study of the effect of particle size and shape of magnetite nanocrystals synthesized by thermal decompositions of iron salts on both their magnetism and their longitudinal and transverse relaxivities, r1 and r2, respectively.	Ferrosoferric Oxide	81-90	CD1b molecule	Homo sapiens	232-241
24245112-0	2013	Silica-coated magnetite nanoparticles labeled by nimotuzumab, a humanised monoclonal antibody to epidermal growth factor receptor: preparations, specific targeting and bioimaging.	Ferrosoferric Oxide	14-23	epidermal growth factor receptor	Homo sapiens	97-129
23662623-2	2013	One possible secondary reaction is the involvement of NO3(-) and nitrite (NO2(-)) with magnetite, a mixed valence Fe(2+)/Fe(3+) mineral found in many natural environments.	Ferrosoferric Oxide	87-96	NBL1, DAN family BMP antagonist	Homo sapiens	54-57
23662623-4	2013	This study investigates NO3(-) and NO2(-) reactivity with magnetite under anoxic conditions using batch kinetic experiments across a range of pH values (5.5-7.5) and in the presence of added dissolved Fe(2+).	Ferrosoferric Oxide	58-67	NBL1, DAN family BMP antagonist	Homo sapiens	24-27
23533767-4	2013	Magnetite nanoparticles were conjugated with NPrCAP to introduce thermotherapeutic and immunotherapeutic effects through nonapoptotic cell death and generation of heat shock protein (HSP) upon exposure to alternating magnetic field (AMF).	Ferrosoferric Oxide	0-9	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	183-186
21940222-2	2011	FTIR data show an increase in alpha-helix and beta-sheet content when lysozyme interaction with magnetite nanoparticles (Fe(3)O(4) (PEG+CM-CTS) NPs) which indicates that the lysozyme would adopt a more compact conformation state.	Ferrosoferric Oxide	96-105	lysozyme	Homo sapiens	70-78
22111689-0	2012	A facile synthesis of PEG-coated magnetite (Fe3O4) nanoparticles and their prevention of the reduction of cytochrome c.	Ferrosoferric Oxide	33-42	cytochrome c, somatic	Homo sapiens	106-118
23010993-2	2012	Here we report the fabrication of pure magnetite nanoparticles, less than ten nanometers in size, using the cage-shaped protein apoferritin (Fe(3)O(4)-ferritin).	Ferrosoferric Oxide	39-48	ferritin heavy chain 1	Homo sapiens	128-139
22578697-2	2012	The ability of magnetite (Fe(3)O(4)) to activate persulfate (PS) and H(2)O(2) for the oxidation of IBP at near neutral pH was evaluated as well.	Ferrosoferric Oxide	15-24	DEF6 guanine nucleotide exchange factor	Homo sapiens	99-102
21978585-3	2011	These issues were addressed by separately studying reactions of As(V) with magnetite, commercial ZVI, and acid-treated ZVI.	Ferrosoferric Oxide	75-84	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	64-69
21978585-5	2011	Adsorption of As(V) on magnetite was fast with pH dependence similar to previous reports using oxic conditions.	Ferrosoferric Oxide	23-32	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-19
21940222-2	2011	FTIR data show an increase in alpha-helix and beta-sheet content when lysozyme interaction with magnetite nanoparticles (Fe(3)O(4) (PEG+CM-CTS) NPs) which indicates that the lysozyme would adopt a more compact conformation state.	Ferrosoferric Oxide	96-105	lysozyme	Homo sapiens	174-182
21506536-3	2011	Because of the permeable character expected for both citrate and IGF-1 coatings surrounding the magnetite cores, an appropriate analysis of their electrophoretic mobility must be addressed.	Ferrosoferric Oxide	96-105	insulin like growth factor 1	Homo sapiens	65-70
21506536-8	2011	In addition, it is also demonstrated that the external layer of IGF-1 exerts a shielding effect on the surface charge of citrate-magnetite particles, as suggested by the mobility reduction upon contacting the particles with the hormone.	Ferrosoferric Oxide	129-138	insulin like growth factor 1	Homo sapiens	64-69
20732712-5	2010	The surface coated magnetite nanoparticles were activated with either N-hydroxysulfosuccinimide or tresyl chloride for covalent immobilization of tissue plasminogen activator (tPA).	Ferrosoferric Oxide	19-28	plasminogen activator, tissue type	Sus scrofa	146-174
21476527-3	2011	Colloidal characteristics of PEO-magnetite nanoparticles with different anchors for attaching PEO to magnetite were examined in PBS.	Ferrosoferric Oxide	33-42	twinkle mtDNA helicase	Homo sapiens	29-32
20395065-5	2011	RESULTS: In seven MRI sessions of clinically presumptive active tumor, gadoteridol-DSC showed low rCBV in three and high rCBV in four, whereas ferumoxytol-DSC showed high rCBV in all seven sessions (p = 0.002).	Ferrosoferric Oxide	143-154	desmocollin 3	Homo sapiens	155-158
20395065-8	2011	CONCLUSION: We conclude that DSC-MRI with a blood pool agent such as ferumoxytol may provide a better monitor of tumor rCBV than DSC-MRI with gadoteridol.	Ferrosoferric Oxide	69-80	desmocollin 3	Homo sapiens	29-32
20207773-2	2011	The Fe(2+)/NO-3 /OH(-) molar ratio of 3 : 1 : 5 led to the formation of magnetic nanoparticles mainly composed of magnetite (Fe3O4) and maghemite (gamma-Fe2O3).	Ferrosoferric Oxide	114-123	NBL1, DAN family BMP antagonist	Homo sapiens	11-15
20732712-5	2010	The surface coated magnetite nanoparticles were activated with either N-hydroxysulfosuccinimide or tresyl chloride for covalent immobilization of tissue plasminogen activator (tPA).	Ferrosoferric Oxide	19-28	plasminogen activator, tissue type	Sus scrofa	176-179
21137981-1	2010	This is most probably the first time that covalently binding of Human serum paraoxonase 1 (PON1) to superparamagnetic magnetite nanoparticles via carbodiimide activation was investigated and presented in this study.	Ferrosoferric Oxide	118-127	paraoxonase 1	Homo sapiens	76-89
21137981-1	2010	This is most probably the first time that covalently binding of Human serum paraoxonase 1 (PON1) to superparamagnetic magnetite nanoparticles via carbodiimide activation was investigated and presented in this study.	Ferrosoferric Oxide	118-127	paraoxonase 1	Homo sapiens	91-95
20552997-3	2010	As compared to bare magnetite particles, the hybrids show a high binding capacity for As(III) and As(V), whose presence in the drinking water in wide areas of South Asia has been a huge problem.	Ferrosoferric Oxide	20-29	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	98-103
20721410-2	2010	Our previous results demonstrated antiaggregation effects of magnetite nanoparticles in the case of protein lysozyme, however, they have yet to be supported by biological samples containing peptides/proteins preaggregated in vivo.	Ferrosoferric Oxide	61-70	lysozyme	Homo sapiens	108-116
20621808-0	2010	Surface-modification-directed controlled adsorption of serum albumin onto magnetite nanocuboids synthesized in a gel-diffusion technique.	Ferrosoferric Oxide	74-83	albumin	Homo sapiens	55-68
20621808-6	2010	We report controlled adsorption behavior of bovine serum albumin (BSA) by surface modification of magnetite nanocuboids with different functional groups.	Ferrosoferric Oxide	98-107	albumin	Homo sapiens	51-64
21137737-0	2010	One-pot reaction to synthesize PEG-coated hollow magnetite nanostructures with excellent magnetic properties.	Ferrosoferric Oxide	49-58	progestagen associated endometrial protein	Homo sapiens	31-34
20201089-8	2010	Patients receiving ferumoxytol also had increases in blood transferrin saturation (TSAT) and ferritin values.	Ferrosoferric Oxide	19-30	transferrin	Homo sapiens	59-70
20202646-0	2010	Silica coated magnetite particles for magnetic removal of Hg2+ from water.	Ferrosoferric Oxide	14-23	polycystin 1, transient receptor potential channel interacting pseudogene 2	Homo sapiens	58-61
30011621-0	2010	Preparation of chitosan/magnetite composite beads and their application for removal of Pb(II) and Ni(II) from aqueous solution.	Ferrosoferric Oxide	24-33	submaxillary gland androgen regulated protein 3B	Homo sapiens	87-104
20071339-4	2010	In cells treated with siRNA to knockdown mDia and then subjected to tensile force using collagen-coated magnetite beads attached to beta1 integrins, actin assembly was inhibited at bead contact sites.	Ferrosoferric Oxide	104-113	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	132-137
30011621-6	2010	These results permitted to conclude that chitosan/magnetite nanocomposite beads could serve as a promising adsorbent not only for Pb(II) and Ni(II) (pH=4-6) but also for other heavy metal ions in wastewater treatment technology.	Ferrosoferric Oxide	50-59	submaxillary gland androgen regulated protein 3B	Homo sapiens	130-147
18655002-1	2008	Magnetic iron(II, III) oxide (magnetite, Fe(3)O(4)) nanoparticles were used to selectively enrich phosphopeptides from tryptic digests of bovine beta-casein and from tryptic digest mixtures containing bovine beta-casein, cytochrome c, bovine serum albumin, and horse heart myoglobin.	Ferrosoferric Oxide	9-28	LOC104968582	Bos taurus	221-233
19524625-4	2009	We developed here block copolymer-coated magnetite nanoparticles for pancreatic cancer imaging, by means of a chelation between the carboxylic acid groups in poly(ethylene glycol)-poly(aspartic acid) block copolymer (PEG-PAsp) and Fe on the surface of the iron oxide nanoparticles.	Ferrosoferric Oxide	41-50	carboxypeptidase B1	Homo sapiens	221-225
19167810-2	2009	Two types of iron (II, III) oxides were used as heterogeneous catalysts and characterized by XRD, Mossbauer spectroscopy, BET surface area, particle size and chemical analyses.	Ferrosoferric Oxide	13-34	delta/notch like EGF repeat containing	Homo sapiens	122-125
19176796-8	2009	There was a greater mean increase in transferrin saturation (TSAT) with ferumoxytol compared with oral iron at day 35 (P < 0.0001).	Ferrosoferric Oxide	72-83	transferrin	Homo sapiens	37-48
18655002-1	2008	Magnetic iron(II, III) oxide (magnetite, Fe(3)O(4)) nanoparticles were used to selectively enrich phosphopeptides from tryptic digests of bovine beta-casein and from tryptic digest mixtures containing bovine beta-casein, cytochrome c, bovine serum albumin, and horse heart myoglobin.	Ferrosoferric Oxide	9-28	albumin	Bos taurus	242-255
18655002-1	2008	Magnetic iron(II, III) oxide (magnetite, Fe(3)O(4)) nanoparticles were used to selectively enrich phosphopeptides from tryptic digests of bovine beta-casein and from tryptic digest mixtures containing bovine beta-casein, cytochrome c, bovine serum albumin, and horse heart myoglobin.	Ferrosoferric Oxide	30-39	LOC104968582	Bos taurus	221-233
18655002-1	2008	Magnetic iron(II, III) oxide (magnetite, Fe(3)O(4)) nanoparticles were used to selectively enrich phosphopeptides from tryptic digests of bovine beta-casein and from tryptic digest mixtures containing bovine beta-casein, cytochrome c, bovine serum albumin, and horse heart myoglobin.	Ferrosoferric Oxide	30-39	albumin	Bos taurus	242-255
18061239-8	2008	The high efficiency of the composite Fe(0)/Fe3O4 for Cr(VI) reduction is discussed in terms of a special mechanism where an electron is transferred from Fe(0) to magnetite to reduce Fe(oct)3+ to Fe(oct)2+, which is active for Cr(VI) reduction.	Ferrosoferric Oxide	162-171	POU class 5 homeobox 1	Homo sapiens	182-190
18061239-6	2008	Experiments with composites based on Fe(0)/alpha-Fe2O3, Fe(0)/gamma-Fe2O3 and Fe(0)/FeOOH showed very low activities, suggesting that Fe(oct)2+ in the magnetite structure plays an important role in the reaction.	Ferrosoferric Oxide	151-160	POU class 2 homeobox 2	Homo sapiens	134-142
18061239-8	2008	The high efficiency of the composite Fe(0)/Fe3O4 for Cr(VI) reduction is discussed in terms of a special mechanism where an electron is transferred from Fe(0) to magnetite to reduce Fe(oct)3+ to Fe(oct)2+, which is active for Cr(VI) reduction.	Ferrosoferric Oxide	162-171	POU class 2 homeobox 2	Homo sapiens	195-203
17869324-10	2008	However, XRD results showed that magnetite was produced in the reaction of Cu(II) and GR-F and SEM shows the production of nano-size particles which were not fully identified in this study.	Ferrosoferric Oxide	33-42	growth hormone releasing hormone	Homo sapiens	75-90